Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Dare Bioscience (DARE) Shares Outstanding (Weighted Average) (2016 - 2025)

Dare Bioscience's Shares Outstanding (Weighted Average) history spans 11 years, with the latest figure at $12.8 million for Q3 2025.

  • For Q3 2025, Shares Outstanding (Weighted Average) rose 47.34% year-over-year to $12.8 million; the TTM value through Sep 2025 reached $12.8 million, up 47.34%, while the annual FY2021 figure was $1.4 million, 27.64% down from the prior year.
  • Shares Outstanding (Weighted Average) reached $12.8 million in Q3 2025 per DARE's latest filing, up from $8.9 million in the prior quarter.
  • In the past five years, Shares Outstanding (Weighted Average) ranged from a high of $85.5 million in Q1 2023 to a low of $1.4 million in Q3 2022.
  • Average Shares Outstanding (Weighted Average) over 5 years is $27.2 million, with a median of $8.7 million recorded in 2024.
  • Peak YoY movement for Shares Outstanding (Weighted Average): tumbled 93.05% in 2021, then skyrocketed 4462.3% in 2022.
  • A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $61.2 million in 2021, then tumbled by 97.74% to $1.4 million in 2022, then surged by 426.31% to $7.3 million in 2023, then grew by 19.1% to $8.7 million in 2024, then surged by 47.34% to $12.8 million in 2025.
  • Per Business Quant, the three most recent readings for DARE's Shares Outstanding (Weighted Average) are $12.8 million (Q3 2025), $8.9 million (Q2 2025), and $8.8 million (Q1 2025).